A fast growing drug co........
Duramed Pharmaceuticals, Inc. Hosts First Quarter 2001 Conference Call
CINCINNATI, Apr 18, 2001 /PRNewswire via COMTEX/ -- Duramed Pharmaceuticals,
Inc. (Nasdaq: DRMD) invites investors to listen to its conference call that will
be broadcast live over the Internet on Wednesday, May 2, 2001, at 10:00 a.m. EST
with Duramed's senior management.
What: Duramed Pharmaceuticals Inc. First Quarter 2001 Conference Call
When: 10:00 AM EST on May 2, 2001
Where: videonewswire.com
How: Live over the Internet -- Simply log on to the web at the address
above
Contact: Duramed Investor Relations, 513-731-9900 or Lisa Carlton-Wilson,
In-Site Communications, Inc., 212-759-3929
About the Company
Duramed Pharmaceuticals, Inc. develops, manufactures and markets prescription
drug products. The company's business strategy emphasizes products with
attractive market opportunities and potentially limited competition due to
technological barriers to entry, focusing on women's health and the hormone
replacement therapy market. The company's mission is to be the premier supplier
of solid oral dose hormone products.
Duramed's containment manufacturing facility for the production of hormones
distinguishes the company from most competitors. The facility incorporates
enclosed product flow and state-of-the-art environmental controls to ensure
purity, stability, and tablet uniformity for its hormone products.
The company's stock is traded on Nasdaq using the symbol DRMD. Additional
information about the company can be found on the World Wide Web at
www.duramed.com and www.cenestin.com .
If you are unable to participate during the live webcast, the call will be
archived on the Web site www.duramed.com/investors. To access the replay, click
on the web cast logo.
(Minimum Requirements to listen to broadcast: The RealPlayer software,
downloadable free from www.real.com/products/player/index.html, and at least a
14.4Kbps connection to the Internet. If you experience problems listening to the
broadcast, send an email to webmaster@vdat.com.)
SOURCE Duramed Pharmaceuticals, Inc.
CONTACT: Duramed Investor Relations, 513-731-9900; or Lisa Carlton-
Wilson of In-Site Communications, Inc., 212-759-3929
URL: duramed.com
prnewswire.com
(C) 2001 PR Newswire. All rights reserved.
-0- |
